Insider · CIK 0001843601

Patel Sandip I

Reports to the SEC for 5 companies · TAMPA, FL

sec.gov

Transactions

Companies

Filings

CIK

0001843601

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-14	AKTXAkari Therapeutics PlcM Exercise/Conversion	Director	MExercise/Conversion	+3,866 sh	$0.00	+$1.546	32,691
2026-10-14	AKTXAkari Therapeutics PlcM Exercise/Conversion	Director	MExercise/Conversion	+6,186 sh	$0.00	+$2.474	38,877
2026-10-14	AKTXAkari Therapeutics Plc · Pre-Funded Warrant to Purchase ADSsM Exercise/Conversion	Director	MExercise/Conversion	−3,866 sh	$16.16	−$62.5K	0
2026-10-14	AKTXAkari Therapeutics Plc · Pre-Funded Warrant to Purchase ADSsM Exercise/Conversion	Director	MExercise/Conversion	−6,186 sh	$16.16	−$100K	0
2026-10-05	AKTXAkari Therapeutics PlcA Award	Director	AAward	+4,313 sh	$7.90	+$34.1K	28,825
2026-10-01	ATCHAtlasClear Holdings, Inc. · Stock Option (right to buy)A Award	Director, CFO and General Counsel	AAward	+777K sh	—	—	777,332
2026-09-25	ATCHAtlasClear Holdings, Inc.A Award	Director, CFO and General Counsel	AAward	+50K sh	$0.20	+$9,875	905,130
2026-09-25	ATCHAtlasClear Holdings, Inc.P Purchase	Director, CFO and General Counsel	PPurchase	+50K sh	$0.20	+$9,875	905,130
2026-09-24	ATCHAtlasClear Holdings, Inc.A Award	Director, CFO and General Counsel	AAward	+50K sh	$0.22	+$10.9K	855,130
2026-09-24	ATCHAtlasClear Holdings, Inc.P Purchase	Director, CFO and General Counsel	PPurchase	+50K sh	$0.22	+$10.9K	855,130
2026-08-18	AKTXAkari Therapeutics PlcA Award	Director	AAward	+12.1K sh	$7.90	+$95.6K	24,512
2026-08-18	AKTXAkari Therapeutics Plc · Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2026-08-18	AKTXAkari Therapeutics Plc · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2026-07-14	ATCHAtlasClear Holdings, Inc. · Stock Option (right to buy)A Award	Director, CFO and General Counsel	AAward	+45K sh	—	—	45,000
2026-07-14	ATCHAtlasClear Holdings, Inc. · Stock Option (right to buy)A Award	Director, CFO and General Counsel	AAward	+731K sh	—	—	731,030
2025-12-16	AKTXAkari Therapeutics Plc · Warrants to purchase American Depositary Shares ("ADRs")P Purchase	Director	PPurchase	+247K sh	—	—	247,462
2025-12-16	AKTXAkari Therapeutics Plc · Pre-Funded Warrants to purchase ADRsP Purchase	Director	PPurchase	+247K sh	$0.40	+$100K	247,462
2025-12-16	AKTXAkari Therapeutics Plc · Warrants to purchase ADRsP Purchase	Director	PPurchase	+155K sh	—	—	154,664
2025-12-16	AKTXAkari Therapeutics Plc · Pre-Funded Warrants to purchase ADRsP Purchase	Director	PPurchase	+155K sh	$0.40	+$62.5K	154,664
2025-03-20	AKTXAkari Therapeutics Plc · Stock Option (Right to Buy)A Award	Director	AAward	+175K sh	—	—	175,000
2025-03-20	AKTXAkari Therapeutics Plc · Stock Option (Right to Buy)A Award	Director	AAward	+225K sh	—	—	225,000
2025-03-06	AKTXAkari Therapeutics PlcA Award	Director	AAward	+44.6K sh	$1.12	+$50K	496,499
2025-03-06	AKTXAkari Therapeutics Plc · Series A Warrants (Right to Buy)A Award	Director	AAward	+44.6K sh	$1.12	+$50K	44,642
2025-03-06	AKTXAkari Therapeutics Plc · Series B Warrants (Right to Buy)A Award	Director	AAward	+44.6K sh	$1.12	+$50K	44,642
2024-11-14	Peak Bio, Inc.C Conversion	Director	CConversion	+763K sh	—	—	763,316
2024-11-14	Peak Bio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−763K sh	—	—	0
2024-11-14	Peak Bio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−67.7K sh	—	—	0
2024-11-14	Peak Bio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−68.9K sh	—	—	0
2024-11-14	Peak Bio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−47.4K sh	—	—	0
2024-11-14	Peak Bio, Inc.Convertible NotesC Conversion	Director	CConversion	—	—	—	0
2024-11-14	Peak Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−400K sh	—	—	0
2024-03-20	ATCHAtlasClear Holdings, Inc. · WarrantsJ Other	Director, CFO and General Counsel	JOther	+354K sh	—	—	354,088
2024-02-09	ATCHAtlasClear Holdings, Inc.J Other	Director, CFO and General Counsel	JOther	+202K sh	—	—	243,194
2024-02-09	Quantum FinTech Acquisition CorpD Disposition to Issuer	Director	DDisposition to Issuer	−41.3K sh	—	—	0
2023-03-09	Monterey Innovation Acquisition CorpS Sale	Director, 10% Owner	SSale	−570K sh	$0.01	−$3,420	1,342,500
2023-03-09	Monterey Innovation Acquisition CorpJ Other	Director, 10% Owner	JOther	+75K sh	—	—	1,417,500
2021-02-05	Quantum FinTech Acquisition CorpP Purchase	Director	PPurchase	+501 sh	$10.34	+$5,177.835	41,334

Recent filings

Accepted (ET)
Oct 16 17:204
Patel Sandip I0001493152-26-047456
SEC(opens sec.gov)
Oct 24
Patel Sandip I0001493152-26-045546
SEC(opens sec.gov)
Sep 284
Patel Sandip I0001493152-26-044471
SEC(opens sec.gov)
Sep 284/A
Patel Sandip I0001493152-26-044629
SEC(opens sec.gov)
Jul 164
Patel Sandip I0001493152-26-033630
SEC(opens sec.gov)
Dec 184
Patel Sandip I0001493152-25-028421
SEC(opens sec.gov)
Apr 294
Patel Sandip I0000950170-25-060298
SEC(opens sec.gov)

Companies

Address

C/O AKARI THERAPEUTICS PLC 401 EAST JACKSON STREET, SUITE 3300

TAMPA, FL, 33602